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associated with grip strength and
muscle size in the elderly
Alixe HM Kilgour1,2,5*, Charlotte Firth6, Rowan Harrison2, Paul Moss6, Mark E Bastin1,3, Joanna M Wardlaw1,3,
Ian J Deary1,4 and John M Starr1,2Abstract
Background: Sarcopenia is an important cause of morbidity and mortality in older adults, with immunosenescence
and inflammation being possible underlying mechanisms. We investigated the relationship between latent
cytomegalovirus (CMV) infection, Interleukin 6 (IL-6) levels, muscle size and strength in a group of healthy older
community-dwelling people.
Methods: Participants were healthy volunteers from the Lothian Birth Cohort 1936 study. Participants had IL-6 level
and CMV antibody titre measured at age 70 years and grip strength and a volumetric T1-weighted MRI brain scan
(allowing measurement of neck muscle cross-sectional area (CSA)) at age 73. Markers of childhood deprivation were
adjusted for in the analysis due to correlations between childhood deprivation and latent CMV infection.
Results: 866 participants were studied; 448 men (mean age 72.48 years, sd 0.70) and 418 women (mean age 72.51
years, sd 0.72). In men, CMV seropositivity was associated with smaller neck muscle CSA (p = 0.03, partial eta
squared = 0.01), even after adjustment for IL-6 levels. Neck muscle CSA was not associated with CMV seropositivity
in women, or CMV antibody titre or IL-6 level in either sex. Grip strength associated negatively with IL-6 level (right
grip strength p<0.00001, partial eta squared 0.032 and left grip strength p<0.00001, partial eta squared 0.027) with
or without adjustment for CMV serostatus or antibody titre. CMV status and antibody titre were not significantly
associated with grip strength in either hand.
Conclusion: These findings support the hypothesis that there is a relationship between markers of
immunosenescence (i.e. CMV serostatus and IL6 level) and low muscle mass and strength and longitudinal studies
in older cohorts are now required to investigate these relationships further.
Keywords: Sarcopenia, Grip strength, Cytomegalovirus, Interleukin-6, ImmunosenescenceIntroduction
Sarcopenia refers to the decline in both muscle mass and
function that occurs with age [1-3]. It is an important
cause of morbidity and mortality in older adults [4-6].
Longitudinal studies have shown muscle mass to be lost at
approximately 1% per annum and strength to be lost at
2-4% per annum in older adults [7,8]. Despite its clinical
importance, current understanding of the mechanisms* Correspondence: a.kilgour@ed.ac.uk
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reproduction in any medium, provided the orunderlying sarcopenia remains unclear. Immunose-
nescence and inflammation have both been identified as
possible contributing factors. Immunosenescence is the
age-associated impairment of immune function due to
changes in both the innate and adaptive immune response
[9]. These changes lead to a decreased ability to respond
to pathogens, although an agreement on clinical bio-
markers and associated clinical outcomes requires further
research [9].
Seropositivity for cytomegalovirus (CMV, otherwise
known as Human Herpes Virus 5), is common in older
adults [10,11]. Most people are infected in childhood or
young adulthood and become carriers of the virus in aLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Muscle size and strength, CMV and IL-6 baseline
data
Variable Statistic/group Men Women
Total neck muscle CSA (mm2) Mean 2576.6 1814.5
SD 421.0 281.2
n 343 298
Right grip strength (kg) Mean 35.49 21.28
SD 6.82 5.54
n 448 416
Left grip strength (kg) Mean 34.69 19.93
SD 6.57 5.13
n 447 416
CMV status Positive (%) 60.6 69.0
Negative (%) 39.4 31.1
n 439 409
CMV antibody titre Median 60.56 132.11
IQ range 0.47-214.00 2.40-277.78
n 437 406
IL-6 level Median 1.60 1.48
IQ range 1.05-2.42 1.01-2.29
n 425 390
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CMV status in immunosenescence is a topic of current
research, and it remains unclear whether the relationship
is causal or associative. However, latent CMV infection
has been linked to several clinical outcomes, including
frailty and increased mortality. Several studies have
found an association between CMV seropositivity and/or
CMV antibody titre and the presence of atherosclerosis
and coronary heart disease, with some studies also dem-
onstrating a correlation with survival time [15-17].
Other studies have found associations between CMV
and cognitive decline in older adults [18], and all cause
mortality [19].
There is also evidence of an association between CMV
infection and frailty. Aiello et al. [20] found that CMV
antibody titre is negatively associated with the ability to
carry out activities of daily living (ADLs) in elderly Latino
subjects, after correcting for gender and age. However,
this relationship became non-significant after adjusting
for the total number of health conditions, body mass
index, and household income. Schmaltz et al. found an
association between frailty, defined using the Fried cri-
teria, and CMV serostatus in older women [20]. Studies
investigating frailty vary widely on the criteria used for
diagnosis and not all frailty scores contain a measure of
muscle mass [21,22]. Therefore, in order for clear con-
clusions to be drawn about the possible underlying
mechanisms of sarcopenia, it is important to study it as
an independent variable rather than as a component of
a frailty score.
Interleukin 6 (IL-6) is a cytokine known to be part of
the acute phase response, i.e. the initial immune system
reaction to infection or trauma [23]. Increasing age is as-
sociated with latent low grade inflammation; levels of IL-6
appear to increase with age, particularly following the
andropause or menopause [24,25]. In a large cross-
sectional study of septuagenarians, raised IL-6 levels were
associated with reduced muscle mass and strength [26].
However, in a further longitudinal cohort higher IL-6
levels were associated with loss of muscle strength, al-
though no association was found with muscle mass [27].
Several studies investigating the effect of CMV on
frailty and functional ability have adjusted for IL-6 to as-
sess its role as a mediator, as CMV is known to increase
IL-6 gene expression and production in peripheral blood
mononuclear cells [28]. Indeed in the above mentioned
study, Schmaltz et al. found that CMV positive subjects
with high IL-6 levels had a significantly higher preva-
lence of frailty than those with a low IL-6 level [20].
Also, data from the Women’s Health and Aging Studies
found that IL-6 appeared to modulate the effect of CMV
antibody titre on frailty as an outcome (measured using
the Fried criteria), although the effect did not reach stat-
istical significance [29].We could find no previous studies which have looked
at the association between muscle mass and CMV
serostatus or antibody titre. Furthermore we found only
one study which addressed the relationship between
CMV serostatus and handgrip strength [21], an import-
ant marker of muscle function in older age, and that
study only looked at women. As detailed above, IL-6
may play an important mediatory role in these relation-
ships and it is therefore important to study this in tan-
dem with CMV status. In this study we investigated the
relationship between latent CMV infection, IL-6 level
and markers of sarcopenia (muscle size and strength) in
a healthy older cohort of community-dwelling men and
women.
Results
There were 866 participants in wave 2 of the LBC1936
study; 448 men (mean age 72.48 years, sd 0.70) and 418
women (mean age 72.51 years, sd 0.72). This represents
79.4% of the participants who attended at the first wave
of testing aged 70 years (n=1091). Baseline data for neck
muscle CSA, right and left grip strength, CMV
serostatus, CMV antibody titre and IL-6 levels are shown
in Table 1. Baseline data for measures of childhood
deprivation are shown in Table 2.
We assessed associations between IL-6 and CMV anti-
body titre (using Spearman’s rho correlations) and CMV
serostatus (using the Wilcoxon independent samples test)
with age, height, weight, the muscle variables and the
Table 2 Childhood deprivation baseline data
Variable Statistic/group Men Women
Overcrowding index (age 11) Median 1.20 1.20
IQ range 0.86-1.67 0.80-1.67
n 447 416
Indoor/outdoor toilet (age 11) Indoor (%) 87.5 90.0
Outdoor (%) 12.5 10.0
n 447 418
Father’s social class I (%) 6.9 7.3
II (%) 21.5 17.2
III (%) 56.7 54.7
IV (%) 6.9 13.3
V (%) 7.9 7.6
n 404 384
Years spent in full time education Median 10 10
IQ range 10-12 10-12
n 448 418
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ation between CMV serostatus and indoor/outdoor toilet
was analysed using the chi-square test. In men, being
CMV seropositive or having a high CMV titre is associated
with all the markers of childhood deprivation. In women,Table 3 Wilcoxon independent samples test (CMV serostatus)
and IL-6 level) (p values)
Male
CMV status (pos/neg)a CMV tit
Age in days at wave 2 .68
(.50) (.
Height in cm −2.08 -
(.04) (.
Weight in kg 1.44
(.15) (.
Total neck muscle CSA (mm2) −1.60 -
(.11) (.
Grip strength right hand (kg) -.62 -
(.54) (.
Grip strength left hand (kg) −1.95 -
(.05) (.
Overcrowding index age 11 4.53
(<.001) (<.00
Father’s job class as a number 3.82
(<.001) (<.00
No. of years of full-time education −3.07 -
(<.01) (<.00
Indoor=1 or outdoor=2 toilet at age 11 0.47*
(.02) (.
aWilcoxon independent samples test statistic (and associated p values) for CMV stat
analysed using the chi-square test and shows *the odds ratio for being CMV seropo
bThe columns for CMV titre and IL-6 titre show the Spearman’s rho correlation withbeing CMV seropositive or having a high CMV titre is as-
sociated with a higher overcrowding index and lower so-
cial class of their father and in addition a high CMV titre
is associated with fewer years of formal education. In men,
IL-6 levels only significantly correlate with the number of
years of full time education (i.e. the more years of educa-
tion the lower the IL-6 level), whereas in women all the
markers of childhood deprivation correlate with a higher
IL-6 level, except for the indoor/outdoor toilet question. If
IL-6 was acting as mediator for CMV infection (i.e. CMV
infection causes inflammation, raising IL6 levels, which
causes increased sarcopenia), we would expect a correl-
ation between the two variables. However, the Spearman’s
rho correlation between IL-6 and CMV antibody titre was
non-significant (rho=0.06, p=0.07), while a Wilcoxon inde-
pendent samples test for IL-6 and CMV serostatus was
also non-significant (test statistic 1.28, p=0.20).
General linear models (ANCOVAs) were then created
for each muscle variable separately with each measure of
immune status (ie CMV status, CMV titre and IL-6 level)
before rerunning the models of CMV status and antibody
titre adjusting for IL-6 status also. Tables 4 and 5 contain
the results for the ANCOVA for CMV serostatus and neck
muscle CSA, and IL-6 and grip strength. The p value gives
the significance of the independent variable’s associationand Spearman’s rho correlations (CMV antibody titre
Female
reb IL-6 titreb CMV status (pos/neg)a CMV titreb IL-6 titreb
.09 .09 2.32 .17 .08
06) (.08) (.02) (<.01) (.14)
.11 -.12 −2.50 -.09 .00
02) (.01) (.01) (.07) (.95)
.07 .16 −1.06 .02 .30
15) (<.01) (.29) (.71) (<.001)
.06 .09 1.02 .09 .21
26) (.10) (.31) (.12) (<.001)
.05 -.25 −2.81 -.10 -.07
34) (<.001) (.01) (.04) (.16)
.10 -.25 −2.04 -.08 -.08
03) (<.001) (.04) (.12) (.11)
.17 .03 3.56 .16 .10
1) (.56) (<.001) (<.01) (.04)
.19 .03 2.51 .14 .16
1) (.55) (.01) (<.01) (<.01)
.17 -.13 −1.57 -.11 -.10
1) (.01) (.12) (.01) (.04)
.10 .04 0.69* .06 .05
03) (.37) (.33) (.18) (.30)
us and all predictor variables except indoor/outdoor toilet age 11, which was
sitive if indoor toilet age 11.
the predictor variables (and the associated p value).
Table 4 ANCOVA for CMV status and total neck muscle CSA
Source Sig. Partial eta squared
Age in days at wave 2 .38 <.01
Weight in kg <.001 .22
Sex (Male=1, Female=2) <.001 .42
Overcrowding index age 11 .29 <.01
Indoor=1 or outdoor=2 toilet at age 11 .88 <.01
Father’s job class as a number .70 <.01
No. of years of full-time education .43 <.01
CMV serostatus (neg=1, pos=2) .10 .01
Sex by CMV serostatus .028 .01
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for which Cohen [30] says the following: small ≥0.0099;
medium ≥0.0588; large ≥0.1379.
We found that CMV seropositivity was associated with
a smaller neck muscle CSA in men but not in women
(p = 0.028, partial eta squared = 0.01) (Table 4). In this
model, lower weight and female sex were also associated
with smaller neck muscle CSA. When this model was
corrected for IL-6 level the effect remained significant
(p = 0.047). The model for neck muscle CSA and CMV
antibody titre showed no significant association, both
with and without adjustment for IL-6 level, nor did the
model with IL-6 as predictor variable, without adjusting
for CMV infection.
Weaker grip strength in both right and left hands was
found to be associated with higher IL-6 level; right grip
strength p<0.00001, partial eta squared = 0.032 and left
grip strength p<0.00001, partial eta squared = 0.027
(Table 5). The associations remain strongly positive even
after adjustment for CMV status (p<0.0001) and CMV
antibody titre (p<0.0001). In these models (shown in
Table 5), older age, shorter stature and female sex wereTable 5 ANCOVA for IL-6 titre and grip strength right and
left hands
Right hand Left hand
Source Sig. Partial eta
squared
Sig. Partial eta
squared
Age in days at Wave 2 .005 .01 .004 .01
Height <.001 .08 <.001 .07
Sex (Male=1, Female=2) <.001 .28 <.001 .34
Overcrowding index age 11 .72 .00 .25 .00
Indoor=1 or outdoor=2 toilet
at age 11
.75 .00 .64 .00
Father’s job class as a
number
.95 .00 .65 .00
No. of years of full-time
education
.051 .01 .10 .00
IL-6 Level <.001 .03 <.001 .03also significantly associated with weaker grip strength in
both hands. The models using CMV status and antibody
titre alone were not significantly associated with grip
strength in either hand.
Discussion
This report used data from waves 1 and 2 of a
population-based elderly cohort study, to investigate the
relationship between latent CMV infection, IL-6 levels
and sarcopenia, measured using neck muscle CSA and
grip strength in both hands. There was no significant
group difference for sex, age or CMV status and titre be-
tween those who participated in wave 1 but not wave 2
(n=225) and those who participated in both waves
(n=866) (independent t tests, p>0.05). We found that
men who were seropositive for CMV antibody at age 70
years had a neck muscle CSA on average 4% smaller at
age 73 than men who were seronegative. This effect
remained positive whether adjusting for IL-6 level or
not. It is well documented that muscle mass is lost at
roughly 1% per year [7,8], therefore being a man who is
CMV seropositive in your 70 s confers the same risks of
low muscle bulk as being 4 years older. We did not de-
tect a significant association in women between CMV
serostatus and neck muscle CSA, or between CMV
serostatus and grip strength in either hand. Other stud-
ies have postulated that as CMV seropositivity is so com-
mon in older adults it may be more important to
measure CMV antibody titre itself. However, we found
no association between CMV antibody titre and either
neck muscle CSA or grip strength. This result may indi-
cate that latent CMV infection leads to increased muscle
loss over an extended period, as CMV is commonly ac-
quired in childhood, though there is the possibility of
temporary reactivations of CMV throughout life, and
that the titre reflects the current situation, which may
have less impact on muscle bulk. Longitudinal studies
will be able to explore these relationships further.
IL-6 levels were found to strongly predict grip strength
in both right and left hands in men and women. IL-6 pre-
dicted 3.2% of the variance in right-sided grip strength
and 2.7% of the variance in left-sided grip strength. These
associations remained significant when adjusting for CMV
serostatus or antibody titre. We found no significant asso-
ciation between IL-6 levels and neck muscle CSA. There-
fore our findings do not support previous work that has
found that IL-6 may act as a mediator by which latent
CMV infection causes frailty [20,29].
It is widely accepted that muscle size and strength do
not decline in a parallel manner [31,32], therefore they are
not purely a function of each other and it may be that dif-
ferent factors cause decline in one parameter more than
the other, as our results have shown. Similarly, a study
looking at the effect of IL-6 levels on muscle found a
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not muscle mass [27], again indicating parameter-specific
effects. Also, these results are based on cross-sectional
data and therefore do not necessarily reflect changes with
age. Therefore it could be that individuals with latent
CMV infection or lifelong raised IL6 levels have always
had smaller/weaker muscles, rather than an increased rate
of decline in muscle mass or function with age. However
as sarcopenia is currently diagnosed using reference to
peers or a healthy young population, having a lower peak
muscle mass and function should still be considered risk
factors for sarcopenia. Longitudinal studies may help elu-
cidate these relationships further.
The sole previous study we found that investigated the
relationship between CMV status and grip strength only
included women [21]. They found no significant difference
in grip strength between seropositive and seronegative
women. We have replicated this finding, but found a sex
specific effect between male sex and CMV serostatus.
There is evidence that men lose more muscle mass than
women with age even after correction for body stature
[33], therefore differing factors may play more or less of a
role between the genders. Additionally, their muscles are
larger to start with and therefore a reduction may be easier
to detect.
It is unclear how CMV might directly influence physical
functioning, however latent CMV infection has been iden-
tified as an important component of an immune risk
phenotype that is associated with immunosenescence, in-
flammation, and several latent health conditions observed
with aging [34]. All these may represent possible contribu-
tory mechanisms to sarcopenia. For example, if CMV in-
fection predisposes to cardiovascular disease this, in turn,
might limit exercise and hence loss of muscle strength and
size. Should our findings be confirmed, exploration of po-
tential causal pathways will be warranted.
Raised plasma IL-6 levels are known to increase prote-
olysis within muscle, by upregulating the proteolytic UPP
pathway [35], however it is not known if the degree of in-
crease seen with ageing is enough to cause atrophy and it
is thought that proteolysis is not a major factor in normal
ageing muscle [36]. However, IL-6 may exert its effect
through less direct routes. It is known that IL-6 causes an-
orexia, which would lead to decreased protein substrate.
Also, IL-6 can both activate cortisol secretion and induce
11beta-hydroxysteroid type 1 expression, so it may exert
its effect via the steroid pathway [37,38]. Furthermore, ani-
mal studies have demonstrated that inflammatory cyto-
kines can induce muscle apoptosis by DNA fragmentation
[35], though such models may not represent low level in-
flammatory changes occurring over a prolonged period.
The narrow geographic, age and ethnic mix within the
LBC1936 cohort means this study may not prove gener-
alisable. However, the narrow age range helps to reducethe powerful effect of advancing age on many of the pa-
rameters measured in this and other studies and which
may have lead to the impression of stronger direct rela-
tionships between co-associated variables than is actually
the case. Additionally the size of the sample studied and
the fact that we replicated results in some of our analyses
found in other work is reassuring. The high correlation
between the markers of childhood deprivation and CMV
status were as predicted and raise the possibility that other
correlates of childhood socioeconomic deprivation may be
mediated by CMV infection, although this relationship
may be less strong in other populations. Also, when study-
ing sarcopenia it is important to consider rate of decline
rather than solely cross-sectional measures. Therefore in
the future, longitudinal studies will be crucial in develop-
ing an understanding of these relationships. Finally, the
concept of a homogeneous model of sarcopenia, whereby
all muscle throughout the body ages at the same rate, is
proving increasingly unlikely to be valid with studies
showing rates of muscle ageing to vary around the body
[33,39,40]. Therefore whilst our measure of neck muscle
CSA has previously been shown to correlate strongly to
mid-thigh muscle CSA, it is important to consider that
different factors may worsen or ameliorate muscle ageing
in different muscle groups throughout the body.
Conclusion
In a large population-based elderly cohort study we found
the men who were seropositive for CMV had smaller neck
muscle CSA than men who were seronegative, and this ef-
fect was independent of IL-6 level. We also found that
higher IL-6 levels, but not CMV levels, were strongly asso-
ciated with lower grip strength in both hands in men and
women. These associations were not attenuated when the
model was adjusted for CMV serostatus or antibody titre.
These findings support the hypothesis that there is a rela-
tionship between immunosenescence and markers of
sarcopenia and longitudinal studies are now required to
investigate these relationships further.
Methods
Participants – The Lothian Birth Cohort 1936 (LBC1936)
The LBC1936 study consists of 1091 relatively healthy,
age-homogeneous older people who, at the age of 11
years, participated in the Scottish Mental Survey of
1947, when they sat a general mental ability test, the
Moray House Test number 12 (MHT). The cohort, in-
cluding the imaging protocol, has been described previ-
ously in detail [41,42] At age 70 years they underwent a
series of cognitive tests (including retaking the MHT),
and physical and biochemical tests, at the Wellcome
Trust Clinical Research Facility (WTCRF) at the West-
ern General Hospital, Edinburgh, where 866 returned
for further testing at age 73. All participants gave
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were Caucasian and almost all lived independently in
the Lothian region (Edinburgh city and surrounding
area) of Scotland.
Neck muscle cross-sectional area
In this study we use neck muscle cross-sectional area
(CSA) as a validated measure of muscle size [32]. We have
previously shown in a study of 24 subjects that neck
muscle CSA is strongly correlated with thigh muscle CSA
(R2 = 0.77), which is often used as a proxy for general
muscle bulk. Neck muscle CSA is generally available in
brain MRI studies, whereas thigh muscle CSA is not usu-
ally measured within longitudinal cognitive ageing studies.
Participants underwent a volumetric brain MRI scan as
part of the LBC1936 study. MRI was performed with par-
ticipants in a supine position using a 1.5 T clinical scanner
(Signa HDxt, GE Healthcare, Milwaukee, USA) at the
Brain Research Imaging Centre, University of Edinburgh
(www.bric.ed.ac.uk). A phased array eight channel head
coil was used and inversion recovery prepared volumetric
T1 weighted images were acquired in a coronal plane for
each participant; the scan alignment was perpendicular to
the long axis of the hippocampus determined from a pre-
liminary T2-weighted sagittal sequence. The flip angle was
8°, bandwidth 15.63 KHz, echo time (TE) 4 to 13 ms, repe-
tition time (TR) 9.6 ms and inversion or preparation time
(TI) 500 ms. The field of view (FOV), fixed superiorly at
the cranial vertex, was 25.6 × 25.6 cm, the acquisition
matrix was 192×192, with 160 slices acquired with a slice
thickness of 1.3 mm with no slice gap. These data took
8.13 minutes to acquire per patient.
Neck muscle CSA was measured using a validated tech-
nique as described previously [43]. In summary, the mid-
point of the C2-vertebra was located in the sagittal slice of
a 3D reconstructed image. The image was then converted
to a transverse view and the posterior neck muscles were
outlined using a cursor on a dedicated workstation. The
software then calculated the contained area. The muscles
groups measured were the semispinalis capitis, splenius
capitis and trapezius (measured as a combined group),
and the sternocleidomastoid. Each measurement was
performed three times and the median for each value was
used for the following analyses.
Grip strength
Grip strength was measured with a Jamar Hydraulic
Hand Dynamometer, with all participants performing 3
trials with their right and left hands; the best of the 3 trials
was used for the following analyses.
CMV and IL-6 measures
CMV was measured in plasma samples collected at age
70, using a CMV ELISA assay. Mock and viral-infectedlysate was coated onto ELISA plates and incubated over-
night. Standards (a mixture of three CMV positive
plasma samples) and plasma samples were added to the
plates and incubated for one hour before washing. An
anti-IgG horseradish peroxidase conjugated secondary
antibody was then added to the plate to incubate for one
hour. After washing, TMB substrate was added and the
reaction stopped by addition of 1M HCL. The sample
was assessed using an ELISA reader at 450 nm. To de-
termine CMV titres, mock values were first subtracted
from lysate values. The data were then analysed in
PRISM, and CMV titres were calculated with reference
to the standard curve. Values above 10 were considered
to be seropositive. To ensure accuracy, all samples were
tested in duplicate. IL-6 levels were analysed at the Uni-
versity of Glasgow using high sensitivity ELISA from
R&D Systems. The minimum detectable dose ranged
from 0.016-0.110 pg/mL (mean=0.039 pg/mL). The
intra-assay CV ranged from 6.9 to 7.8%, while the inter-
assay coefficient of variance ranged from 6.6 to 9.6%.Childhood deprivation
At the age 70 assessment, participants were asked to
provide background demographic and environmental in-
formation about their childhood, specifically for when
they were aged about 11 years. Participants reported the
number of people they lived with and the number of
rooms in the house, which was used to calculate an
overcrowding index (people/room). Participants also
reported: whether their household had indoor or out-
door toilet facilities; their father’s occupation to allow
father’s social class to be coded (categorised from I, pro-
fessional, to V, unskilled); and the number of years they
spent in full-time, formal education.Statistical analysis
Descriptive statistics, exploratory analyses and general
linear modeling (Analysis of Covariance; ANCOVA)
were performed using SPSS version 18.0 for Windows
(SPSS Inc, Chicago, Ill, USA). Missing values were ex-
cluded listwise for the ANCOVA analyses. For the
ANCOVA, we constructed baseline models with the
measures of neck muscle CSA and grip strength (right
and left) as dependent (i.e. outcome) variables and CMV
serostatus, CMV antibody titre and IL-6 level as inde-
pendent variables, adjusting for age, gender and either
height or weight, as a measure of body size, and the four
measures of childhood deprivation. Total neck muscle
CSA was found to correlate more strongly with weight
(P<0.001), whereas both right and left grip strength cor-
related more strongly with height (p<0.001). Therefore
we used the respective measures for adjustment in each
of the analyses.
Kilgour et al. Immunity & Ageing 2013, 10:33 Page 7 of 8
http://www.immunityageing.com/content/10/1/33Competing interests
The authors declared that they have no competing interests.
Authors’ contributions
AHMK and JMS proposed the hypotheses, performed the analyses and
drafted the manuscript. AHMK performed the neck cross-sectional area
measurements. IJD, JMS, MEB and JMW designed the LBC1936 study. CF, RH
and PM designed and implemented the immunological measurements. All
authors approved the final manuscript.
Acknowledgements
Dr AHM Kilgour was funded during this research by The University of
Edinburgh Centre for Cognitive Ageing and Cognitive Epidemiology, part of
the cross council Lifelong Health and Wellbeing Initiative (G0700704/84698).
Funding from the Biotechnology and Biological Sciences Research Council
(BBSRC), Engineering and Physical Sciences Research Council (EPSRC),
Economic and Social Research Council (ESRC) and Medical Research Council
(MRC) is gratefully acknowledged. The LBC1936 studies have been funded by
Age UK and the MRC. CMV materials were funded as part of a British
Geriatrics Society start-up grant to Dr R Harrison. Ms C Firth is funded by an
Age UK PhD studentship. JMW was part funded by the Scottish Funding
Council through the Scottish Imaging Network, a Platform for Scientific
Excellence (SINAPSE, www.sinapse.ac.uk) Initiative. The funders had no role in
study design, data collection and analysis, decision to publish, or preparation
of the manuscript.
We thank A Gow, C Murray, J Corley, R Henderson and A Pattie at the Centre
of Cognitive Aging and Cognitive Epidemiology, and MV Hernandez, SM
Maniega, N Royle, E Sandeman, I Gerrish, of the Brain Research Imaging
Centre, both of the University of Edinburgh, UK, for demographic and clinical
data collection on the LBC1936. We would also like to thank the LBC1936
Study participants; CD Gray, S Semple, T MacGillivray and staff at the Clinical
Research Imaging Centre, Queen’s Medical Research Institute, University of
Edinburgh, UK; D Job, additional radiographers and other staff at The Brain
Research Imaging Centre, Edinburgh, UK.
Author details
1Centre for Cognitive Ageing and Cognitive Epidemiology, University of
Edinburgh, 7 George Square, Edinburgh EH8 9JZ, UK. 2Geriatric Medicine
Unit, University of Edinburgh, Edinburgh, UK. 3Brain Research Imaging Centre,
Division of Neuroimaging Sciences, University of Edinburgh, Edinburgh, UK.
4Department of Psychology, University of Edinburgh, Edinburgh, UK. 5Clinical
Research Imaging Centre, Queen’s Medical Research Institute, University of
Edinburgh, Edinburgh, UK. 6School for Cancer Sciences, University of
Birmingham, Birmingham B15 2TT, UK.
Received: 5 December 2012 Accepted: 12 August 2013
Published: 13 August 2013
References
1. Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, Martin
FC, Michel JP, Rolland Y, Schneider SM, Topinkova E, Van-dewoude M,
Zamboni M: Sarcopenia: European consensus on definition and
diagnosis. Age Ageing 2010, 39:412–423.
2. Fielding RA, Vellas B, Evans WJ, Bhasin S, Morley JE, Newman AB, Abellan
van Kan G, Andrieu S, Bauer J, Breuille D, Cederholm T, Chandler J, De-
Meynard C, Donini L, Harris T, Kannt A, Keime Guibert F, Onder G,
Papanicolaou D, Rolland Y, Rooks D, Sieber C, Souhami E, Verlaan S,
Zamboni M, Sarcopenia: An undiagnosed condition in older adults.
Current consensus definition: prevalence, etiology, and consequences.
International working group on sarcopenia. J Am Med Dir Assoc 2011,
12:249–256.
3. Muscaritoli M, Anker SD, Argiles J, Aversa Z, Bauer JM, Biolo G, Boirie Y,
Bosaeus I, Cederholm T, Costelli P, Fearon KC, Laviano A, Maggio M, Fanelli
FR, Schneider SM, Schols A, Sieber CC: Consensus definition of sarcopenia,
cachexia and pre-cachexia: Joint document elaborated by special
interest groups (sig) “Cachexia-anorexia in chronic wasting diseases” and
“Nutrition in geriatrics”. Clin Nutr 2010, 29:154–159.
4. Lauretani F, Russo CR, Bandinelli S, Bartali B, Cavazzini C, Di-Iorio A, Corsi
AM, Rantanen T, Guralnik JM, Ferrucci L: Age-associated changes in
skeletal muscles and their effect on mobility: an operational diagnosis of
sarcopenia. J Appl Physiol 2003, 95:1851–1860.5. Baumgartner RN, Koehler KM, Gallagher D, Romero L, Heymsfield SB, Ross
RR, Garry PJ, Lindeman RD: Epidemiology of sarcopenia among the
elderly in New Mexico. Am J Epidemiol 1998, 147:755–763.
6. Rantanen T: Muscle strength, disability and mortality. Scand J Med Sci
Sports 2003, 13:3–8.
7. Goodpaster BH, Park SW, Harris TB, Kritchevsky SB, Nevitt M, Schwartz AV,
Simonsick EM, Tylavsky FA, Visser M, Newman AB, Hlth ABCS: The loss of
skeletal muscle strength, mass, and quality in older adults: the health, aging
and body composition study. J Gerontol Biol Sci & Med Sci 2006, 61:1059–1064.
8. Visser M, Deeg DJH, Lips P: Low vitamin d and high parathyroid hormone
levels as determinants of loss of muscle strength and muscle mass
(sarcopenia): the longitudinal aging study Amsterdam. J Clin Endocrinol
Metab 2003, 88:5766–5772.
9. Pawelec G, Akbar A, Beverley P, Caruso C, Derhovanessian E, Fülöp T,
Griffiths P, Grubeck-Loebenstein B, Hamprecht K, Jahn G, Kern F, Koch SD,
Larbi A, Maier AB, Macallan D, Moss P, Samson S, Strindhall J, Trannoy E,
Wills M: Immunosenescence and cytomegalovirus: where do we stand
after a decade? Immunity & Ageing 2010, 7:13.
10. Lubeck PR, Doerr HW, Rabenau HF: Epidemiology of human
cytomegalovirus (hcmv) in an urban region of Germany: what has
changed? Med Microbiol Immunol 2010, 199:53–60.
11. Lopo S, Vinagre E, Palminha P, Paixao MT, Nogueira P, Freitas MG:
Seroprevalence to cytomegalovirus in the Portuguese population,
2002–2003. Euro Surveill 2011, 16:19896.
12. Soderberg-Naucler C, Nelson JY: Human cytomegalovirus latency and
reactivation - a delicate balance between the virus and its host’s
immune system. Intervirology 1999, 42:314–321.
13. Sinclair J: Human cytomegalovirus: latency and reactivation in the
myeloid lineage. J Clin Virol 2008, 41:180–185.
14. Slobedman B, Cao JZ, Avdic S, Webster B, McAllery S, Cheung AK, Tan JC,
Abendroth A: Human cytomegalovirus latent infection and associated
viral gene expression. Future Microbiol 2010, 5:883–900.
15. Blankenberg S, Rupprecht HJ, Bickel C, Espinola-Klein C, Rippin G, Hafner G,
Ossendorf M, Steinhagen K, Meyer J, Group ftA: Cytomegalovirus infection
with interleukin-6 response predicts cardiac mortality in patients with
coronary artery disease. Circulation 2001, 103:2915–2921.
16. Muhlestein JB, Horne BD, Carlquist JF, Madsen TE, Bair TL, Pearson RR,
Anderson JL: Cytomegalovirus seropositivity and c-reactive protein have
independent and combined predictive value for mortality in patients
with angiographically demonstrated coronary artery disease. Circulation
2000, 102:1917–1923.
17. Strandberg TE, Pitkala KH, Tilvis RS: Cytomegalovirus antibody level and
mortality among community-dwelling older adults with stable
cardiovascular disease. Jama 2009, 301:380–382.
18. Aiello AE, Haan M, Blythe L, Moore K, Gonzalez JM, Jagust W: The influence
of latent viral infection on rate of cognitive decline over 4 years. J Am
Geriatr Soc 2006, 54:1046–1054.
19. Roberts ET, Haan MN, Dowd JB, Aiello AE: Cytomegalovirus antibody
levels, inflammation, and mortality among elderly latinos over 9 years of
follow-up. Am J Epidemiol 2010, 172:363–371.
20. Schmaltz HN, Fried LP, Xue QL, Walston J, Leng SX, Semba RD: Chronic
cytomegalovirus infection and inflammation are associated with
prevalent frailty in community-dwelling older women. J Am Geriatr Soc
2005, 53:747–754.
21. Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J,
Seeman T, Tracy R, Kop WJ, Burke G, McBurnie MA: Cardiovascular Health
study C: frailty in older adults: evidence for a phenotype. J Gerontol Sci &
Med Sci 2001, 56:M146–M156.
22. Rockwood K, Mitnitski A: Frailty in relation to the accumulation of deficits.
J Gerontol A Biol Sci Med Sci 2007, 62:722–727.
23. Heinrich PC, Castell JV, Andus T: Interleukin-6 and the acute phase
response. Biochem J 1990, 265:621–636.
24. Hager K, Machein U, Krieger S, Platt D, Seefried G, Bauer J: Interleukin-6 and
selected plasma-proteins in healthy-persons of different ages. Neurobiol
Aging 1994, 15:771–772.
25. Ershler WB, Keller ET: Age-associated increased interleukin-6 gene
expression, late-life diseases, and frailty. Annu Rev Med 2000, 51:245–270.
26. Visser M, Pahor M, Taaffe DR, Goodpaster BH, Simonsick EM, Newman AB,
Nevitt M, Harris TB: Relationship of interleukin-6 and tumor necrosis factor-
alpha with muscle mass and muscle strength in elderly men and women:
the Health Abc study. J Gerontol Sci & Med Sci 2002, 57:M326–M332.
Kilgour et al. Immunity & Ageing 2013, 10:33 Page 8 of 8
http://www.immunityageing.com/content/10/1/3327. Schaap LA, Pluijm SMF, Deeg DJH, Visser M: Inflammatory markers and loss of
muscle mass (sarcopenia) and strength. Am J Med 2006, 119:e9–e17.
28. Geist LJ, Dai LY: Cytomegalovirus modulates interleukin-6 gene
expression. Transplantation 1996, 62:653–658.
29. Wang GC, Kao WH, Murakami P, Xue QL, Chiou RB, Detrick B, McDyer JF,
Semba RD, Casolaro V, Walston JD, Fried LP: Cytomegalovirus infection
and the risk of mortality and frailty in older women: A prospective
observational cohort study. Am J Epidemiol 2010, 171:1144–1152.
30. Cohen J: Statistical power analysis for the behavioral sciences, ed Second
edition. Hillsdale, New Jersey: Lawrence Erlbaum Associates; 1988.
31. Young A, Stokes M, Crowe M: The size and strength of the quadriceps
muscles of old and young men. Clin Physiol 1985, 5:145–154.
32. Skelton DA, Greig CA, Davies JM, Young A: Strength, power and related
functional ability of healthy people aged 65–89 years. Age Ageing 1994,
23:371–377.
33. Gallagher D, Visser M, De-Meersman RE, Sepulveda D, Baumgartner RN,
Pierson RN, Harris T, Heymsfield SB: Appendicular skeletal muscle mass:
Effects of age, gender, and ethnicity. J Appl Physiol 1997, 83:229–239.
34. Pawelec G, Koch S, Franceschi C, Wikby A: Human immunosenescence: does
it have an infectious component? Ann N Y Acad Sci 2006, 1067:56–65.
35. Skipworth RJE, Stewart GD, Ross JA, Guttridge DC, Fearon KCH: The
molecular mechanisms of skeletal muscle wasting: Implications for
therapy. Surgeon 2006, 4:273–283.
36. Tsujinaka T, Fujita J, Ebisui C, Yano M, Kominami E, Suzuki K, Tanaka K,
Katsume A, Ohsugi Y, Shiozaki H, Monden M: Interleukin 6 receptor
antibody inhibits muscle atrophy and modulates proteolytic systems in
interleukin 6 transgenic mice. J Clin Investig 1996, 97:244–249.
37. Weber MM, Michl P, Auernhammer CJ, Engelhardt D: Interleukin-3 and
interleukin-6 stimulate cortisol secretion from adult human
adrenocortical cells. Endocrinology 1997, 138:2207–2210.
38. Tomlinson JW, Moore J, Cooper MS, Bujalska I, Shahmanesh M, Burt C, Strain
A, Hewison M, Stewart PM: Regulation of expression of 11beta-
hydroxysteroid dehydrogenase type 1 in adipose tissue: Tissue-specific
induction by cytokines. Endocrinology 2001, 142:1982–1989.
39. Janssen I, Heymsfield SB, Wang ZM, Ross R: Skeletal muscle mass and
distribution in 468 men and women aged 18–88 yr. J Appl Physiol 2000,
89:81–88.
40. Gallagher D, Heymsfield SB: Muscle distribution: variations with body
weight, gender, and age. Appl Radiat Isot 1998, 49:733–734.
41. Deary IJ, Gow AJ, Taylor MD, Corley J, Brett C, Wilson V, Campbell H,
Whalley LJ, Visscher PM, Porteous DJ, Starr JM: The Lothian Birth Cohort
1936: A study to examine influences on cognitive ageing from age 11 to
age 70 and beyond. BMC Geriatr 2007, 7:28.
42. Deary IJ, Gow AJ, Pattie A, Starr JM: Cohort profile: the Lothian Birth
Cohorts of 1921 and 1936. Int J Epidemiol 2012, 41:1576–1584.
43. Kilgour A, Subedi D, Gray C, Deary I, Lawrie S, Wardlaw J, Starr J: Design
and validation of a novel method to measure cross-sectional area of
neck muscles included during routine MR brain volume imaging. PLoS
ONE 2012, 7:e34444.
doi:10.1186/1742-4933-10-33
Cite this article as: Kilgour et al.: Seropositivity for CMV and IL-6 levels
are associated with grip strength and muscle size in the elderly.
Immunity & Ageing 2013 10:33.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
